Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02036879 · ClinicalTrials.gov registry record · Early Phase 1
Gender Disparity and Hormones in Cystic Fibrosis
A Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 55
- Enrollment target
NCT02036879 is a Early Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 55 participants.
The verdict
NCT02036879, a Early Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The objective of this study is to investigate the impact of hormones on lung disease in Cystic Fibrosis (CF) patients. Due to improved therapies, CF patients are living longer and healthier lives than they did 20 years ago. However, females have been shown to have a survival disadvantage. The median life expectancy is 33 in women and 37 in men with CF. The hypothesis is that estrogen and/or progesterone negatively impact lung health in CF. Therefore, understanding the impact of sex hormones (including the use of birth control pills) on the disease process is increasingly important. The purpose of this study is to determine if lung function, respiratory symptoms, or various markers of lung health change during different phases of the natural ovulatory cycle in order to understand if estrogen or progesterone hormones are impacting the disease relative to fluctuations in men with stable testosterone levels. The research objectives of this project are to: * Determine if lung function, respiratory symptoms, or various markers of lung health change during different hormonal phases of the ovulatory cycle in women. * Determine if men change lung function, respiratory symptoms, or various markers of lung health over time. * Determine if oral contraceptive pills in women stabilize fluctuations in symptoms and improve lung health.
Interventions
- DRUG Loestrin (norethindrone acetate and ethinyl estradiol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2014-02 |
| Est. Completion | 2018-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02036879
The ClinicalTrials.gov registry entry for NCT02036879 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Loestrin (norethindrone acetate and ethinyl estradiol) is the first listed.
NCT02036879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02036879 about?
NCT02036879 is a clinical study titled "Gender Disparity and Hormones in Cystic Fibrosis". The objective of this study is to investigate the impact of hormones on lung disease in Cystic Fibrosis (CF) patients. Due to improved therapies, CF patients are living longer and healthier lives than they did 20 years ago. However, females have been shown to have a survival disadvantage. The median...
What is the current status of trial NCT02036879?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 55 participants. The study started on 2014-02. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02036879?
The interventions under investigation include: Loestrin (norethindrone acetate and ethinyl estradiol) (DRUG).
Who is sponsoring clinical trial NCT02036879?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.